A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1).

  • Perkins, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date12/10/20 → 31/12/25

Keywords

  • Blood diseases
  • Myelofibrosis
  • Clinical trial

Clinical Trial Phase

  • Phase III (a & b)